Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.
Buckley RF, Townsend DL, Birkenbihl CJ, Cuppels M, Coughlan GT, Seto MT, Brown JA, Properzi MJ, Hönig MC, Li A, Schultz AP, Chhatwal J, Yang HS, Arnold S, Kivisäkk P, James BD, O'Bryant S, Rissman RA, Petersen M, Caldwell JZK, Betthauser T, Oomens JE, Carrigan M, Healy B, Condado JG, Johnson SC, Yau WW, Langford O, Farrell M, Amariglio RE, Rentz DM, Papp KV, Brookmeyer R, Hohman TJ, Donohue M, Aisen PS, Johnson KA, Sperling RA; Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health D; Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health Disparities (HABS-HD), and Wisconsin Registry for Alzheimer’s Prevention (WRAP).
Buckley RF, et al.
JAMA. 2026 Jul 14:e2612556. doi: 10.1001/jama.2026.12556. Online ahead of print.
JAMA. 2026.
PMID: 42449500